Compare ESNT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | CANF |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | Bermuda | Israel |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.8M |
| IPO Year | 2013 | N/A |
| Metric | ESNT | CANF |
|---|---|---|
| Price | $66.86 | $0.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $68.00 | $3.25 |
| AVG Volume (30 Days) | 607.2K | ★ 1.5M |
| Earning Date | 11-07-2025 | 02-03-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.87 | N/A |
| Revenue | ★ $1,263,558,000.00 | $560,000.00 |
| Revenue This Year | $3.87 | $461.72 |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | ★ 2.04 | N/A |
| 52 Week Low | $51.61 | $0.25 |
| 52 Week High | $67.09 | $2.33 |
| Indicator | ESNT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 75.10 | 30.53 |
| Support Level | $64.73 | $0.26 |
| Resistance Level | $62.35 | $0.30 |
| Average True Range (ATR) | 1.16 | 0.03 |
| MACD | 0.43 | -0.00 |
| Stochastic Oscillator | 96.79 | 2.34 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).